文献速递淋巴瘤

伊布替尼-维奈克拉一线治疗CLL:GLOW研究67个月结果

First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival.
PubMed 文献 · Leukemia · 2026-10-02

GLOW III期研究67个月随访显示,在老年/合并症CLL患者中,伊布替尼-维奈克拉较苯丁酸氮芥-奥妥珠单抗持续改善OS(66个月率79.0%对60.8%,HR 0.46)和PFS(66个月率51.7%对18.1%,HR 0.27),并延长无3/4级TEAE的PFS(51.6对30.2个月)。

要点

  • 伊布替尼-维奈克拉一线治疗老年/合并症CLL,67个月随访OS和PFS均优于苯丁酸氮芥-奥妥珠单抗。
  • 固定疗程伊布替尼-维奈克拉使二线治疗需求风险降低77.4%,无3/4级TEAE的PFS延长21.4个月。
  • 治疗结束时MRD不可测者PFS更优,尤其在IGHV未突变患者中。

核心结论

  • 伊布替尼-维奈克拉一线治疗老年/合并症CLL,较苯丁酸氮芥-奥妥珠单抗维持更优OS、PFS并减少二线治疗需求。

研究设计与样本

  • III期GLOW研究(NCT03462719),随机1:1分配至伊布替尼-维奈克拉组(n=106)或苯丁酸氮芥-奥妥珠单抗组(n=105),中位随访67个月。

主要发现

  • 66个月OS率伊布替尼-维奈克拉组79.0%,苯丁酸氮芥-奥妥珠单抗组60.8%(HR 0.46)。
  • 66个月PFS率伊布替尼-维奈克拉组51.7%,苯丁酸氮芥-奥妥珠单抗组18.1%(HR 0.27),不受IGHV/MRD状态影响。
  • 伊布替尼-维奈克拉降低二线治疗需求风险77.4%。
  • 治疗结束时MRD不可测者PFS优于MRD可测者,尤其在IGHV未突变患者中。
  • 无3/4级TEAE的PFS伊布替尼-维奈克拉组51.6个月,苯丁酸氮芥-奥妥珠单抗组30.2个月,延长21.4个月。

临床怎么用

  • 固定疗程伊布替尼-维奈克拉可作为老年/合并症初治CLL患者的一线有效选择,兼顾持久疾病控制与保留后续治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Long-term efficacy and toxicity data are needed to inform optimal first-line treatment for individual patients with chronic lymphocytic leukemia (CLL). We report long-term outcomes of ibrutinib-venetoclax in older/comorbid patients at 67-month median follow-up of the phase III GLOW study (NCT03462719) and report grade 3/4 treatment-emergent adverse event (TEAE)-free progression-free survival (PFS). Patients were randomized 1:1 to ibrutinib-venetoclax (n = 106) or chlorambucil-obinutuzumab (n = 105). Sixty-six-month overall survival (OS) rates were 79.0% and 60.8% for ibrutinib-venetoclax and chlorambucil-obinutuzumab, respectively (hazard ratio [HR] 0.46). Ibrutinib-venetoclax reduced the risk of requiring second-line therapy by 77.4% and continued to improve PFS vs chlorambucil-obinutuzumab (66-month rates: 51.7% vs 18.1%, HR 0.27), regardless of IGHV/measurable residual disease (MRD) status. Ibrutinib-venetoclax-treated patients with undetectable MRD at end-of-treatment had better PFS outcomes than those with detectable MRD, especially in patients with unmutated IGHV. Grade 3/4 TEAE-free PFS was 21.4 months longer for ibrutinib-venetoclax vs chlorambucil-obinutuzumab (51.6 vs 30.2 months). Ibrutinib-venetoclax maintains superior OS, superior PFS, reduction in need for second-line treatment, and longer PFS duration without grade 3/4 TEAEs vs chlorambucil-obinutuzumab. Fixed-duration ibrutinib-venetoclax is an effective first-line treatment option for older/comorbid patients with previously untreated CLL, providing durable disease control and preserving future treatment options.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. U Niemann C, Munir T, Owen C, et al. First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival. Leukemia. 2026. PMID: 42827117. doi:10.1038/s41375-026-03150-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。